Mabvax Therapeutics Holdings Inc. (MBVX) 0.9220 $MBVX
MabVax Therapeutics Selected To Present at 2015 BIO CEO & Investor Conference
PR Newswire - Wed Feb 04, 7:00AM CST
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a cancer diagnostic and immunotherapy company, announced today that it has been selected to make a corporate presentation in the public company program at the upcoming BIO CEO & Investor Conference at 1:00 pm E.T. on Tuesday, February 10th in New York City.
MabVax Therapeutics - "MabVax Therapeutics' Corporate Presentation at BIOTECH Showcase Highlights Progress in 2014 and Announces Plans For 2015"
ACCESSWIRE - Mon Feb 02, 7:08AM CST
New York, NY / ACCESSWIRE / February 2, 2015 / MabVax Therapeutics Holdings, Inc. (OTCQB:MBVX) today published a new blog post on The Chairman's Blog, written by the Company's President and Chief Executive Officer, David Hansen. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
A 4 Million Dollar Deal
Mark Kroenke - Seeking Alpha - Fri Jan 02, 10:26AM CST
It looks like I forgot to add the MabVax (OTCQB: MBVX ) data to the above chart, but it's actually there. The company's market capitalization of 0.004 billion is completely invisible when plotted on the same scale as immuno-oncology giants like Juno...
Missed the Juno IPO? Take a Look at MabVax
ACCESSWIRE - Mon Dec 22, 8:33AM CST
NEW YORK, NY / ACCESSWIRE / December 22, 2014 / When an initial public offering soars over 50% right out of the gate, you almost never get a second chance to buy at the IPO price. Juno Therapeutics (NASDAQ:JUNO), an oncology-focused biotech not even a year and a half old, accomplished just that on Friday when it offered shares at $24 a piece and closed its first trading day just below $37.
JUNO: 40.52 (+0.18), NVS: 102.20 (-0.17)
MabVax Therapeutics Selected To Make Corporate Presentation at January 2015 BIOTECH Showcase
PR Newswire - Thu Dec 11, 7:30AM CST
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) a cancer diagnostic and immunotherapy company, announced today that it has been selected to make a corporate presentation in the public company program at the upcoming BIOTECH Showcase event. The company is scheduled to present at 9:00 am on Wednesday, January 14th in the Powell presentation room at the Parc 55 Wyndham Hotel in San Francisco. MabVax will present a corporate update including highlighting the significant progress made in the last year on the development of its lead antibody candidate HuMab 5B1 as a diagnostic product and therapeutic agent in the diagnosis and treatment of GI cancers and specifically pancreatic cancer. MabVax's CEO David Hansen will also update investors and interested corporate entities on the therapeutic cancer vaccine program, which has two products in late stage Phase II clinical trials. He will also discuss the upcoming Phase II trial in the childhood cancer neuroblastoma for which MabVax received an Orphan Drug Designation from FDA in September of this year.
Delisting of Securities of GT Advanced Technologies, Inc., Dendreon Corporation, MabVax Therapeutics Holdings, Inc., and Tri-Tech Holding Inc. From The Nasdaq Stock Market
GlobeNewswire - Wed Dec 10, 3:05PM CST
The Nasdaq Stock Market announced today that it will delist the common stock of GT Advanced Technologies, Inc. GT Advanced Technologies, Inc.'s stock was suspended on October 16, 2014 and has not traded on Nasdaq since that time.
NDAQ: 49.48 (-0.27)
MabVax At The Intersection Of Vaccine And Antibody Cancer Immunotherapy
Austrolib - at Seeking Alpha - Tue Dec 09, 8:14AM CST
A New Combined Approach to Cancer Immunotherapy is Needed
ACCESSWIRE - Mon Dec 01, 11:35AM CST
NEW YORK, NY / ACCESSWIRE / December 1, 2014 / With the recent bankruptcy of Dendreon Corporation (NASDAQ
NDN) due to disappointing sales of its flagship Provenge prostate cancer vaccine, the future of cancer immunotherapy just got a bit cloudier. While Provenge itself will survive, Dendreon may end up going private in a debt restructuring deal.
DNDN: 0.13 (-0.02), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56)
MabVax Therapeutics And Memorial Sloan-Kettering Cancer Center Report on Potential Use of Dual-Labeled Antibody To Detect and Guide Surgical Removal of Pancreatic Cancer
PR Newswire - Wed Nov 19, 1:00PM CST
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) a clinical stage oncology drug development company in conjunction with the Department of Radiology at Memorial Sloan-Kettering Cancer Center (MSKCC) presented results on the use of MabVax's lead antibody development candidate, HuMab 5B1, as the targeting vehicle carrying two different imaging agents intended to significantly improve the imaging of pancreatic tumors and facilitate more effective cancer resections. The results were presented at the World Molecular Imaging Congress in Seoul, South Korea by Jacob Houghton, Ph.D. and Jason Lewis, Ph.D. of MSKCC. The HuMab 5B1 antibody was conjugated individually to a near-infrared fluorescent agent (NIRF) for optical imaging and desferrioxamine (DFO), a chelate used to radiolabel with Zirconium-89 (89Zr) for PET imaging. Each singly labeled construct performed well in illuminating the targeted tumors. Additionally, a dual-labeled construct was prepared to incorporate the advantages of both modalities into a single construct. The dual-labeled HuMab 5B1 yielded high-resolution PET images of the targeted cancer and its metastases prior to resection while the fluorescent label significantly enhanced the imaging of the tumor and definition of tumor margins during resection in multiple murine models of pancreatic cancer. The imaging agent developed in this study showed exceptional potential as a tool to aid in the diagnosis, staging, and resection of pancreatic cancer.
MabVax Is Under The Radar, But Undervalued: CEO David Hansen
Trevor Lowenthal - at Seeking Alpha - Mon Nov 17, 10:22AM CST
MabVax Therapeutics - "Introducing MabVax Therapeutics: Newly Public Company Achieves Multiple Milestones in Recent Quarter"
ACCESSWIRE - Thu Oct 23, 7:16AM CDT
New York, NY / ACCESSWIRE / October 23, 2014 / MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) today published a new blog post on The Chairman's Blog, written by the Company's President and Chief Executive Officer, David Hansen. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
MabVax Therapeutics Launches Online Corporate Communication Channels and New Website
PR Newswire - Thu Oct 23, 7:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical stage oncology drug development company, announced today a suite of online corporate communication channels to maintain on-going direct communication with shareholders and other interested parties. The Company has launched official portals on social media channels including Facebook, Twitter, LinkedIn, Google+, and The Chairman's Blog.
MabVax Therapeutics Nominates The Fully Human Antibody HuMab 5B1 As The Company's Lead Clinical Development Candidate
PR Newswire - Tue Oct 21, 8:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) a clinical stage oncology drug development company, announced today that it has formally nominated its HuMab 5B1 antibody as a clinical candidate for the diagnosis and treatment of pancreatic and colon cancer. The fully human antibody, recovered from patients undergoing cancer vaccine treatment at Memorial Sloan-Kettering Cancer Center, has entered GMP manufacturing to produce clinical trial supplies for a planned Phase 1 program to begin in the second half of 2015. The development plan calls for dual Phase 1 clinical trials to take place simultaneously. One program will be aimed at demonstrating the utility of the radio-labeled antibody as a novel PET imaging agent for the diagnosis and management of pancreatic cancer. The second program will determine the safety and potential utility of the full-length antibody as a treatment for the same cancer.
MabVax Therapeutics reports change in common stock ticker symbol
M2 - Mon Oct 13, 8:30AM CDT
Oncology company MabVax Therapeutics Holdings said on Friday that its common shares will commence trading under the new trading symbol MBVX (OTCQB:MBVX.).
MabVax Therapeutics Selected To Present at 2015 BIO CEO & Investor Conference
PR Newswire - Wed Feb 04, 7:00AM CST
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a cancer diagnostic and immunotherapy company, announced today that it has been selected to make a corporate presentation in the public company program at the upcoming BIO CEO & Investor Conference at 1:00 pm E.T. on Tuesday, February 10th in New York City.
MabVax Therapeutics - "MabVax Therapeutics' Corporate Presentation at BIOTECH Showcase Highlights Progress in 2014 and Announces Plans For 2015"
ACCESSWIRE - Mon Feb 02, 7:08AM CST
New York, NY / ACCESSWIRE / February 2, 2015 / MabVax Therapeutics Holdings, Inc. (OTCQB:MBVX) today published a new blog post on The Chairman's Blog, written by the Company's President and Chief Executive Officer, David Hansen. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
A 4 Million Dollar Deal
Mark Kroenke - Seeking Alpha - Fri Jan 02, 10:26AM CST
It looks like I forgot to add the MabVax (OTCQB: MBVX ) data to the above chart, but it's actually there. The company's market capitalization of 0.004 billion is completely invisible when plotted on the same scale as immuno-oncology giants like Juno...
Missed the Juno IPO? Take a Look at MabVax
ACCESSWIRE - Mon Dec 22, 8:33AM CST
NEW YORK, NY / ACCESSWIRE / December 22, 2014 / When an initial public offering soars over 50% right out of the gate, you almost never get a second chance to buy at the IPO price. Juno Therapeutics (NASDAQ:JUNO), an oncology-focused biotech not even a year and a half old, accomplished just that on Friday when it offered shares at $24 a piece and closed its first trading day just below $37.
JUNO: 40.52 (+0.18), NVS: 102.20 (-0.17)
MabVax Therapeutics Selected To Make Corporate Presentation at January 2015 BIOTECH Showcase
PR Newswire - Thu Dec 11, 7:30AM CST
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) a cancer diagnostic and immunotherapy company, announced today that it has been selected to make a corporate presentation in the public company program at the upcoming BIOTECH Showcase event. The company is scheduled to present at 9:00 am on Wednesday, January 14th in the Powell presentation room at the Parc 55 Wyndham Hotel in San Francisco. MabVax will present a corporate update including highlighting the significant progress made in the last year on the development of its lead antibody candidate HuMab 5B1 as a diagnostic product and therapeutic agent in the diagnosis and treatment of GI cancers and specifically pancreatic cancer. MabVax's CEO David Hansen will also update investors and interested corporate entities on the therapeutic cancer vaccine program, which has two products in late stage Phase II clinical trials. He will also discuss the upcoming Phase II trial in the childhood cancer neuroblastoma for which MabVax received an Orphan Drug Designation from FDA in September of this year.
Delisting of Securities of GT Advanced Technologies, Inc., Dendreon Corporation, MabVax Therapeutics Holdings, Inc., and Tri-Tech Holding Inc. From The Nasdaq Stock Market
GlobeNewswire - Wed Dec 10, 3:05PM CST
The Nasdaq Stock Market announced today that it will delist the common stock of GT Advanced Technologies, Inc. GT Advanced Technologies, Inc.'s stock was suspended on October 16, 2014 and has not traded on Nasdaq since that time.
NDAQ: 49.48 (-0.27)
MabVax At The Intersection Of Vaccine And Antibody Cancer Immunotherapy
Austrolib - at Seeking Alpha - Tue Dec 09, 8:14AM CST
A New Combined Approach to Cancer Immunotherapy is Needed
ACCESSWIRE - Mon Dec 01, 11:35AM CST
NEW YORK, NY / ACCESSWIRE / December 1, 2014 / With the recent bankruptcy of Dendreon Corporation (NASDAQ
NDN) due to disappointing sales of its flagship Provenge prostate cancer vaccine, the future of cancer immunotherapy just got a bit cloudier. While Provenge itself will survive, Dendreon may end up going private in a debt restructuring deal. DNDN: 0.13 (-0.02), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56)
MabVax Therapeutics And Memorial Sloan-Kettering Cancer Center Report on Potential Use of Dual-Labeled Antibody To Detect and Guide Surgical Removal of Pancreatic Cancer
PR Newswire - Wed Nov 19, 1:00PM CST
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) a clinical stage oncology drug development company in conjunction with the Department of Radiology at Memorial Sloan-Kettering Cancer Center (MSKCC) presented results on the use of MabVax's lead antibody development candidate, HuMab 5B1, as the targeting vehicle carrying two different imaging agents intended to significantly improve the imaging of pancreatic tumors and facilitate more effective cancer resections. The results were presented at the World Molecular Imaging Congress in Seoul, South Korea by Jacob Houghton, Ph.D. and Jason Lewis, Ph.D. of MSKCC. The HuMab 5B1 antibody was conjugated individually to a near-infrared fluorescent agent (NIRF) for optical imaging and desferrioxamine (DFO), a chelate used to radiolabel with Zirconium-89 (89Zr) for PET imaging. Each singly labeled construct performed well in illuminating the targeted tumors. Additionally, a dual-labeled construct was prepared to incorporate the advantages of both modalities into a single construct. The dual-labeled HuMab 5B1 yielded high-resolution PET images of the targeted cancer and its metastases prior to resection while the fluorescent label significantly enhanced the imaging of the tumor and definition of tumor margins during resection in multiple murine models of pancreatic cancer. The imaging agent developed in this study showed exceptional potential as a tool to aid in the diagnosis, staging, and resection of pancreatic cancer.
MabVax Is Under The Radar, But Undervalued: CEO David Hansen
Trevor Lowenthal - at Seeking Alpha - Mon Nov 17, 10:22AM CST
MabVax Therapeutics - "Introducing MabVax Therapeutics: Newly Public Company Achieves Multiple Milestones in Recent Quarter"
ACCESSWIRE - Thu Oct 23, 7:16AM CDT
New York, NY / ACCESSWIRE / October 23, 2014 / MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) today published a new blog post on The Chairman's Blog, written by the Company's President and Chief Executive Officer, David Hansen. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
MabVax Therapeutics Launches Online Corporate Communication Channels and New Website
PR Newswire - Thu Oct 23, 7:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical stage oncology drug development company, announced today a suite of online corporate communication channels to maintain on-going direct communication with shareholders and other interested parties. The Company has launched official portals on social media channels including Facebook, Twitter, LinkedIn, Google+, and The Chairman's Blog.
MabVax Therapeutics Nominates The Fully Human Antibody HuMab 5B1 As The Company's Lead Clinical Development Candidate
PR Newswire - Tue Oct 21, 8:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) a clinical stage oncology drug development company, announced today that it has formally nominated its HuMab 5B1 antibody as a clinical candidate for the diagnosis and treatment of pancreatic and colon cancer. The fully human antibody, recovered from patients undergoing cancer vaccine treatment at Memorial Sloan-Kettering Cancer Center, has entered GMP manufacturing to produce clinical trial supplies for a planned Phase 1 program to begin in the second half of 2015. The development plan calls for dual Phase 1 clinical trials to take place simultaneously. One program will be aimed at demonstrating the utility of the radio-labeled antibody as a novel PET imaging agent for the diagnosis and management of pancreatic cancer. The second program will determine the safety and potential utility of the full-length antibody as a treatment for the same cancer.
MabVax Therapeutics reports change in common stock ticker symbol
M2 - Mon Oct 13, 8:30AM CDT
Oncology company MabVax Therapeutics Holdings said on Friday that its common shares will commence trading under the new trading symbol MBVX (OTCQB:MBVX.).
